BioSpace News Archive

U.S. FDA Approves Addition of Overall Survival and Other Secondary Endpoint Data to NUBEQA ® (darolutamide) Prescribing Information Phase III data showed treatment with NUBEQA resulted in a 31% reduction in risk of death, with a statistically significant improvement in overall survival (OS) compared to placebo (HR=0.69, 95% CI 0.53-0.88; p=0.003), giving men with non-metastatic castration-resistant prostate cancer (nmCRPC)

Strata Oncology, Inc., a precision oncology company advancing molecular indications for cancer therapies, today announced that Dan Rhodes, Ph.D., co-founder and Chief Executive Officer of Strata Oncology will present at the upcoming virtual J.P. Morgan 39th Annual Healthcare Conference on January 13, 2021, at 8:05 a.m. Eastern Time

Biomea Fusion, Inc., a precision oncology company dedicated to developing innovative medicines targeting genomically defined alterations in both hematologic and solid cancers, announced today that it will present at the upcoming virtual 39th Annual J.P. Morgan Healthcare Conference.

Ginkgo Bioworks announced today that Jason Kelly , Ginkgo Bioworks CEO and co-founder, will present at the 39 th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 10:25 AM Eastern Time . His presentation will cover Ginkgo’s response to COVID-19, from rapid optimization of vaccine manufacturing to commun

Retractable Technologies, Inc. announced that its Board of Directors has declared dividends to holders of its Series I Class B and Series II Class B Convertible Preferred Stock in the amounts of $10,041 and $39,050, respectively.

Qosina recently added 12 new filter options for fluid and gas applications. The company’s extensive filter product line includes a variety of hydrophilic and hydrophobic filters, transducer protectors, and an assortment of NRFit™ filters that comply with the ISO 80369-6 standard. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210108005537/en/ Qosina

39th Annual JP Morgan Healthcare Conference 23rd Annual Needham Growth Conference

Graphite Bio, a next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced that Josh Lehrer, M.Phil, M.D., chief executive officer, will present an overview of Graphite Bio’s corporate strategy, business priorities and upcoming clinical milestones at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11,

Company to Webcast Presentation Tuesday, January 12, 2021 at 5:30 p.m. ET

Evaxion Biotech A/S (the “Company” or “Evaxion”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today that it has filed a registration statement on Form F-1 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of the Company’s